Pirenzepine is under clinical development by Winsantor and currently in Phase II for Diabetic Peripheral Neuropathy. According to GlobalData, Phase II drugs for Diabetic Peripheral Neuropathy have an 11% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Pirenzepine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pirenzepine overview

Pirenzepine (WST-057) is under development for the treatment of diabetic peripheral neuropathy, chemotherapy induced peripheral neuropathy and HIV related associated distal sensory polyneuropathy (DSP). The drug candidate is applied topically. It acts by targeting muscarinic acetylcholine type 1 receptors (M1R).

It was also under development for the treatment of Pain.

Winsantor overview

Winsantor., is a biotechnology company that focused on the discovery and development of treatments for peripheral neuropathies. The company is headquartered in United States.

For a complete picture of Pirenzepine’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.